Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1994-3-4
|
| pubmed:abstractText |
1. We have investigated the potency and duration of action of isoprenaline and a range of beta-adrenoceptor agonists as relaxants of inherent tone in human superfused, isolated bronchial smooth muscle, a tissue reported to contain a homogeneous population of beta 2-adrenoceptors. 2. All of the beta-adrenoceptor agonists caused concentration-related inhibition of inherent tone, with isoprenaline having an EC50 of 27 nM. The rank order of agonist potency was: formoterol > or = -salmeterol > or = clenbuterol > fenoterol = isoprenaline > terbutaline > or = salbutamol > quinprenaline. 3. Relaxant responses to salmeterol were fully reversed by the selective beta 2-adrenoceptor blocking drug, ICI 118551, demonstrating the involvement of beta 2-adrenoceptors. 4. Rt50, i.e. the time taken for 50% recovery from the effects of an EC50 concentration of agonist, differed considerably between the different beta 2-adrenoceptor agonists. Most agonists were short-acting, having Rt50 values less than 13 min. Quinprenaline was of moderate duration, with an Rt50 value of > or = 20 min. In contrast, salmeterol was extremely long-acting, with no sign of recovery within 4 h. 5. Estimates of relative potency and duration of action were similar to those previously determined for these agonists in the guinea-pig isolated trachea. These results suggest, therefore, that guinea-pig trachea is a suitable alternative to human bronchus for the evaluation of the actions of beta-adrenoceptor agonists on airways smooth muscle.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-1679656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-1686740,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-184872,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-2544117,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-2611492,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-2704248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-2904183,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-3427271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-4380700,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-4396897,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-4656622,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-6144342,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7905340-8095419
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0007-1188
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
110
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1112-6
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:meshHeading | |
| pubmed:year |
1993
|
| pubmed:articleTitle |
Effects of beta-adrenoceptor agonists in human bronchial smooth muscle.
|
| pubmed:affiliation |
Department of Cardiovascular and Respiratory Pharmacology, Glaxo Group Research Ltd., Ware, Herts.
|
| pubmed:publicationType |
Journal Article
|